WuXi AppTec Raises 2026 Guidance After Strong Nine-Month Results
WuXi AppTec reported a 38.6% rise in nine-month revenue and lifted its full-year 2026 revenue outlook. The company published the results on October 26, 2026.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
WuXi AppTec, a Chinese pharmaceutical CRDMO, reported results for the first three quarters of 2026, ending September 30. Revenue reached RMB 45.54 billion, up 38.6% year on year. Adjusted non-IFRS net profit rose 74.4% to RMB 18.38 billion, and the adjusted non-IFRS gross margin widened by 7.7 percentage points to 54.8%.
The company also raised its full-year 2026 outlook. Revenue is now expected at RMB 61.0-61.9 billion, compared with the earlier RMB 58.5-60.5 billion range. Backlog for continuing operations grew 36.4% to RMB 76.74 billion. Cash dividends paid in the first three quarters totaled RMB 6.22 billion.
why it matters
The higher guidance and growing backlog point to sustained demand for contract research and manufacturing services from drugmakers. For investors in the Shanghai and Hong Kong listings, the results signal strong operating momentum at one of the sector's largest players.
market impact
Pharma sector in China and Hong Kong: strong results and higher guidance support WuXi AppTec shares
tags
instruments
sources
- WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers' Products and CRDMO Model — TradingView, 26 October 2026 at 09:25 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗